首页|长春瑞滨并顺铂治疗晚期NSCLC病人骨髓抑制发生时间与近期疗效相关性

长春瑞滨并顺铂治疗晚期NSCLC病人骨髓抑制发生时间与近期疗效相关性

扫码查看
目的 探讨接受长春瑞滨并顺铂方案(NP方案)一线化疗的晚期非小细胞肺癌(NSCLC)病人骨髓抑制发生时间与近期疗效的关系.方法 共收集晚期NSCLC病人138例,均接受至少2周期NP方案一线化疗,按骨髓抑制发生时间分为早期骨髓抑制组(第1~2周期化疗期间发生骨髓抑制)和非早期骨髓抑制组(第3~6周期化疗期间发生骨髓抑制或化疗期间无骨髓抑制),分析其与近期化疗效果的关系.结果 早期骨髓抑制组、非早期骨髓抑制组治疗客观有效率分别为71.8%(69/96)、35.7%,两组比较差异有显著性(x2=16.04,P<0.05);两组肿瘤控制率分别为81.3%、64.3%,两组比较差异无显著性(P>0.05).结论 对于接受NP方案一线化疗的晚期NSCLC病人,早期发生骨髓抑制是影响近期化疗效果的有利因素,对化疗效果具有一定的预测价值.
ASSOCIATION BETWEEN TIME OF ONSET OF MYELOSUPPRESSION AND SHORT-TERM RESPONSE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER TREATED WITH VINORELBINE AND CISPLATIN
Objective To investigate the association between time of onset of myelosuppression and short-term response in patients with advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and cisplatin (NP regimen).Methods A total of 138 patients with advanced NSCLC who received at least two cycles of first-line chemotherapy with NP regimen were enrolled,and according to the time of onset of myelosuppression,these patients were divided into early myelosuppression group (myelosuppression occurred during the 1-2 cycles of chemotherapy) and non-early myelosuppression group (myelosuppression occurred during the 3-6 cycles of chemotherapy or no myelosuppression occurred during chemotherapy).The association between time of onset of myelosuppression and short-term response was analyzed.Results The objective response rate was 71.8% (69/96) in the early myelosuppression group and 35.7% in the non-early myelosuppression group,and there was a significant difference between the two groups (x2 =16.04,P<0.05).There was no significant difference in tumor control rate between the two groups (81.3% vs 64.3%,P>0.05).Conclusion In patients with advanced NSCLC who receive the first-line chemotherapy with NP regimen,early onset of myelosuppression is a favorable factor for short-term response to chemotherapy and has a certain value in predicting the efficacy of chemotherapy.

carcinoma, non-small-cell lungdrug therapyhematological toxicitytreatment outcome

刘海新、毕迎惠、郭成业、张亚琨

展开 >

青岛市市立医院(集团)西院区肿瘤一科,山东青岛266011

青岛市市立医院(集团)东院区肿瘤科,山东青岛266011

癌,非小细胞肺 药物疗法 骨髓抑制 治疗结果

2017

齐鲁医学杂志
青岛大学医学院

齐鲁医学杂志

影响因子:0.609
ISSN:1008-0341
年,卷(期):2017.32(3)
  • 1
  • 10